by Steven M. Opal
Critical Care 2016, 20:397 – Published: 16 December 2016
The emergence of multi-drug resistant (MDR) microbial pathogens threatens the very foundation upon which standard antibacterial chemotherapy is based. Recent discoveries of plasmid-transferable genes that mediate resistance to carbapenems and colistin indicate that the last defensive wall against multi-drug resistant (MDR) pathogens has already been breached. We now face the uncomfortable reality that the post-antibiotic era has arrived when dealing with pan-resistant bacterial pathogens. We need to consider our remaining options and develop new ones in a world where antibiotics can no longer be counted upon to cure infections. Non-antibiotic opportunities to treat serious bacterial infections exist as possible options.